MGLL and schizophrenia: The hydrolytic activity of MAGL is thought to be responsible for terminating approximately 85% of the signal from 2-AG.53 Since problems with the endocannabinoid system have been suggested to play a role in a number of neurological diseases such as addiction, pain, anxiety, and schizophrenia, small molecule tools to modulate endocannabinoid activity without unwanted psychoactive effects are desirable both as therapeutics and probes of endocannabinoid function.54 For these reasons, MAGL has recently been identified as a target of interest for imaging with PET/SPECT.